On Tuesday, FibroGen Inc (NASDAQ: FGEN) opened lower -2.51% from the last session, before settling in for the closing price of $0.40. Price fluctuations for FGEN have ranged from $0.33 to $2.93 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Annual sales at Healthcare sector company slipped by -2.51% over the past five years. Company’s average yearly earnings per share was noted 65.07% at the time writing. With a float of $93.27 million, this company’s outstanding shares have now reached $98.77 million.
Let’s look at the performance matrix of the company that is accounted for 486 employees. In terms of profitability, gross margin is 76.65%, operating margin of -91.86%, and the pretax margin is -98.64%.
FibroGen Inc (FGEN) Insider and Institutional Ownership
A key investor’s attitude towards the stock of the Biotechnology industry is another important factor to consider. The insider ownership of FibroGen Inc is 7.10%, while institutional ownership is 56.39%. The most recent insider transaction that took place on Jun 12 ’24, was worth 25,884. In this transaction Chief Medical Officer of this company bought 22,123 shares at a rate of $1.17, taking the stock ownership to the 82,123 shares. Before that another transaction happened on Mar 07 ’24, when Company’s CEO bought 50,000 for $1.91, making the entire transaction worth $95,470. This insider now owns 470,178 shares in total.
FibroGen Inc (FGEN) Latest Financial update
If we go through the results of last quarter, which was made public on 6/30/2024, the company posted -0.65 earnings per share (EPS) for the quarter, besting the agreed prediction (set at -0.68) by 0.03. Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.22 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 65.07% per share during the next fiscal year.
FibroGen Inc (NASDAQ: FGEN) Trading Performance Indicators
Check out the current performance indicators for FibroGen Inc (FGEN). In the past quarter, the stock posted a quick ratio of 1.24. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 0.22.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -1.71, a number that is poised to hit -0.30 in the next quarter and is forecasted to reach -0.69 in one year’s time.
Technical Analysis of FibroGen Inc (FGEN)
FibroGen Inc (NASDAQ: FGEN) saw its 5-day average volume 0.87 million, a negative change from its year-to-date volume of 2.57 million. As of the previous 9 days, the stock’s Stochastic %D was 53.05%. Additionally, its Average True Range was 0.07.
During the past 100 days, FibroGen Inc’s (FGEN) raw stochastic average was set at 2.32%, which indicates a significant decrease from 22.21% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 73.08% in the past 14 days, which was lower than the 139.28% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $0.7818, while its 200-day Moving Average is $1.1662. Nevertheless, the first resistance level for the watch stands at $0.3980 in the near term. At $0.4109, the stock is likely to face the second major resistance level. The third major resistance level sits at $0.4219. If the price goes on to break the first support level at $0.3741, it is likely to go to the next support level at $0.3631. The third support level lies at $0.3502 if the price breaches the second support level.
FibroGen Inc (NASDAQ: FGEN) Key Stats
There are currently 99,474K shares outstanding in the company with a market cap of 38.66 million. Presently, the company’s annual sales total 147,750 K according to its annual income of -284,230 K. Last quarter, the company’s sales amounted to 50,640 K and its income totaled -15,540 K.
